Anupam Rasayan India Ltd - 543275 - Closure of Trading Window
The trading window of the Company shall remain closed from Monday, July 01, 2024 till the end of 48 hours after the announcement / declaration of the unaudited standalone and consolidated financial results for the quarter ended June 30, 2024. Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
We wish to inform you that the Nomination and Remuneration Committee at its meeting held today, has approved the issue and allotment of 48,792 fully paid-up equity shares of face value of Rs. 10/- each under Anupam - Employees Stock Option Plan 2020. Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI(LODR) Regulations, 2015, we wish to inform the Exchanges that the members of the management team of the Company will attend the conference and meet the investors on June 18, 2024 (Tuesday) Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we wish to inform the Exchanges that the members of the management team of the Company will meet the investor on June 14, 2024 (Friday). Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Submission of Transcript of Earnings Call on the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2024. Anupam Rasayan India Ltd - 543275 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30(6) of the SEBI (LODR) Regulations, 2015, we wish to inform the exchanges that audio recording of the Earnings Call on the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2024, held by the Company on Tuesday, May 21, 2024, at 03:30 p.m. IST, is available on the Company's website.
Anupam Rasayan India Results Earnings Call for Q4FY24
Conference Call with Anupam Rasayan India Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript. Anupam Rasayan India Ltd - 543275 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A(2) of the SEBI (LODR) Regulations, 2015, please find enclosed herewith the Annual Secretarial Compliance Report for the financial year ended March 31, 2024, issued by M. D. Baid & Associates, Practicing Company Secretaries, Surat. Anupam Rasayan India Ltd - 543275 - Statement Of Deviation Or Variation In The Use Of Proceeds Of Qualified Institutions Placement For The Quarter Ended March 31, 2024
Pursuant to Regulation 32 of the SEBI (LODR) Regulations, 2015, please find enclosed herewith the statement of no deviation or variation for the quarter ended March 31, 2024, in the use of proceeds raised by way of QIP. Q4FY24 Quarterly & FY24 Annual Result Announced for Anupam Rasayan India Ltd.
Speciality Chemicals company Anupam Rasayan India announced consolidated Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Total revenue for Q4FY24 was at Rs 4,130 million as compared to Rs 5,042 million in Q4FY23; down 18% YoY. EBITDA (incl. other income) was at Rs 1,047 million in Q4FY24 as compared to Rs 1,416 million in Q4FY23 – degrowth of 26% YoY, this would translate into 25% EBITDA margin in this quarter. Profit After Tax was at Rs 405 million in Q4FY24 as compared to Rs 726 million in Q4FY23 - degrowth of 44% YoY. FY24 Financial Highlights: Total revenue for FY24 was at Rs 15,053 million as compared to Rs 16,105 million in FY23; down 7% YoY. EBITDA (incl. other income) was at Rs 4,109 million as compared to Rs 4,399 million in FY23 – degrowth of 7.0% YoY, this would translate into 27% EBITDA margin. Profit After Tax was at Rs 1,674 million as compared to Rs 2,168 million in FY23 - degrowth of 23% YoY. Speaking on the performance, Anand Desai, Managing Director, Anupam Rasayan commented, “Indian chemical industry including spec chem industry has faced significant headwinds during the last year. However, despite the de-growth in the top-line, we have been able to sustain our profitability and maintain margins at 27% levels on a full year consolidated basis. During the year, the Agro chemical industry in particular faced challenges, however our past sustained efforts in expanding our pharma and polymer portfolio have started yielding results leading to pharma contributing over 9% of revenue in FY24, up from 4% last year. We expect pharma and polymer segment each to further increase their revenue share in double digits by next year. In FY2024, we have focused on expanding our customers, products and end market applications. We have added 17 new molecules, 4 new MNCs including 2 Japanese majors and expanded contribution from polymer and pharma which going forward will lead to balanced product portfolio from end market perspective. We believe that headwinds in the industry may continue for the next two quarters. However, financial year 2025 will be a year of growth for us with our major focus on polymer and pharmaceutical space.” Result PDF